Commitments and Contingencies - Additional Information (Detail)	0 Months Ended	3 Months Ended	6 Months Ended					12 Months Ended	3 Months Ended
	Jun. 30, 2013 USD ($)	Sep. 30, 2013 USD ($)	Mar. 31, 2014 USD ($)	Mar. 31, 2014 EUR (€)	Mar. 31, 2013	Mar. 31, 2014 Patents [Member]	Mar. 31, 2014 SRI Litigation [Member] Inventor Plaintiff	Sep. 30, 2013 SRI Litigation [Member] USD ($)	Sep. 30, 2013 Prior to Fiscal 2013 [Member] USD ($)
Commitments and Contingencies [Line Items]
Litigation expense								$ 100,000
Number of inventors on patent royalty claim							2
Number of plaintiffs							1
Unreimbursed legal expenses	1,300,000
Payment received on unreimbursed legal expenses		1,000,000
Legal expenses									600,000
Reimbursement of legal fee, Percentage					75.00%
Additional shares of common stock to stockholders			480,059	480,059
License agreement commencement date			2006-03	2006-03
Annual minimum payments for licenses			275,000	200,000
Exchange rate relating to license payment			$ 1.3752
Future minimum payments associated with license			3,700,000
Patent expiry date						2027-09
Additional maximum amount payable on successful achievement of specified milestones to sellers of PR Pharma			2,500,000
Indemnification period			5 years	5 years
Accrual for contingency			$ 0